Promoters and Institutions have not increased their holdings in Suven Life Sciences, indicating a lack of confidence from smart money.

Both Institutional and Public shareholding have decreased year-over-year, contrasting with sector averages that show no change, suggesting broader selling pressure.

In a sector where the best performer saw an institutional increase of 18.88%, Suven's stagnant position is concerning, reflecting potential underperformance.